Global Penny Stocks To Watch In August 2025

Global markets have been buoyed by favorable trade deals, pushing major indices like the S&P 500 and Nasdaq Composite to record highs. Amidst this backdrop of economic optimism, investors are increasingly exploring opportunities beyond the traditional large-cap stocks. Penny stocks, despite their old-fashioned name, continue to attract attention for their potential value in smaller or newer companies. By focusing on those with strong financials and growth prospects, investors can uncover promising opportunities in this often-overlooked segment of the market.

Top 10 Penny Stocks Globally

Click here to see the full list of 3,832 stocks from our Global Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Guizhou Yibai Pharmaceutical (SHSE:600594)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Guizhou Yibai Pharmaceutical Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical products in China with a market cap of CN¥3.44 billion.

Operations: The company generates its revenue primarily from the Chinese market, amounting to CN¥2.10 billion.

Market Cap: CN¥3.44B

Guizhou Yibai Pharmaceutical, with a market cap of CN¥3.44 billion and revenue of CN¥2.10 billion, primarily serves the Chinese market. Despite being unprofitable and experiencing increased losses at a rate of 49.8% annually over five years, the company has reduced its debt to equity ratio from 35.2% to 33.5%. Its short-term assets (CN¥1.7 billion) cover both short-term and long-term liabilities comfortably, while its net debt to equity ratio is satisfactory at 15.9%. The management team and board are experienced with average tenures of 6.7 and 14.5 years respectively, providing stability amid financial challenges.

• Take a closer look at Guizhou Yibai Pharmaceutical's potential here in our financial health report.
• Understand Guizhou Yibai Pharmaceutical's track record by examining our performance history report.

Zhejiang Sunflower Great Health (SZSE:300111)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zhejiang Sunflower Great Health Co., Ltd. operates in the health industry and has a market cap of CN¥4.53 billion.

Operations: The company generates revenue of CN¥318.91 million from its pharmaceutical industry segment.

Market Cap: CN¥4.53B

Zhejiang Sunflower Great Health operates with a market cap of CN¥4.53 billion and generates revenue of CN¥318.91 million, indicating its active presence in the pharmaceutical sector. The company is debt-free, eliminating concerns over interest coverage and showcasing financial prudence by maintaining assets that comfortably exceed both short- and long-term liabilities. Despite a seasoned management team with an average tenure of 8.8 years, recent financial performance has been mixed; earnings growth has turned negative at -79.4% over the past year, while net profit margins have declined from 9.6% to 2.2%. Additionally, one-off gains impacted last year's results significantly.

• Click here to discover the nuances of Zhejiang Sunflower Great Health with our detailed analytical financial health report.
• Assess Zhejiang Sunflower Great Health's previous results with our detailed historical performance reports.

Youngy Health (SZSE:300247)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Youngy Health Co., Ltd. is a company that manufactures, exports, and sells sauna products in China with a market cap of CN¥3.37 billion.

Operations: Youngy Health Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥3.37B

Youngy Health Co., Ltd., with a market cap of CN¥3.37 billion, has demonstrated robust financial health by remaining debt-free and maintaining short-term assets of CN¥979.8 million that surpass its liabilities. The company has achieved profitable growth over the past five years, though recent earnings growth of 57.4% fell below its historical average but still outpaced the industry significantly. Despite a relatively inexperienced board, the management team is seasoned with an average tenure of six years. Youngy Health's stable weekly volatility and improved profit margins further underscore its operational stability in a competitive sector.

• Dive into the specifics of Youngy Health here with our thorough balance sheet health report.
• Examine Youngy Health's past performance report to understand how it has performed in prior years.

Summing It All Up

• Discover the full array of 3,832 Global Penny Stocks right here.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com